{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:02:40Z","timestamp":1785816160833,"version":"3.56.0"},"reference-count":97,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can extend over a few decades, and therefore treatment planning is predicated on continual reassessment of traditional risk features (age, prior thrombosis) to evaluate the need for cytoreduction besides foundational therapy with low-dose aspirin and stringent phlebotomy. Shorter- and longer-term patient goals should be considered in light of several variables such as comorbid conditions (especially cardiovascular risk factors), disease symptoms, and the risk-benefit profile of available drugs. While hydroxyurea has been the pro forma choice of cytoreduction for many practitioners over the last half-century, the more recent regulatory approvals of ruxolitinib and ropeginterferon-alfa-2b, based on phase 3 randomized trials, highlight an expanding portfolio of active drugs. Obtaining high-level evidence for short-term clinical trial endpoints such as hematocrit control, symptom burden\/quality of life, splenomegaly, and JAK2 V617F allele burden lies within the timeline of most studies. However, in many cases, it may not be possible to adequately power trials to capture significant differences in the typically low event rates of thrombosis as well as longer-horizon endpoints such as evolution to myelofibrosis and acute myeloid leukemia and survival. This Perspective highlights the challenges of addressing these data gaps and outstanding questions in the emerging treatment landscape of PV.<\/jats:p>","DOI":"10.1182\/blood.2022015680","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T18:18:51Z","timestamp":1646936331000},"page":"2871-2881","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-6156","authenticated-orcid":false,"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute\/Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2022051215233670500_B1","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood."},{"issue":"13","key":"2022051215233670500_B2","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood."},{"issue":"2","key":"2022051215233670500_B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJMp038177","article-title":"Daily aspirin: only half the answer","volume":"350","author":"Spivak","year":"2004","journal-title":"N Engl J Med."},{"issue":"1","key":"2022051215233670500_B4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJMe1213283","article-title":"Polycythemia vera, the hematocrit, and blood-volume physiology","volume":"368","author":"Spivak","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"2022051215233670500_B5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia."},{"key":"2022051215233670500_B6","article-title":"Myeloproliferative Neoplasms, version 2.2021","author":"NCCN Clinical Practice Guidelines in Oncology"},{"issue":"10","key":"2022051215233670500_B7","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.exphem.2015.05.013","article-title":"Comparative long-term effects of interferon \u03b1 and hydroxyurea on human hematopoietic progenitor cells","volume":"43","author":"King","year":"2015","journal-title":"Exp Hematol."},{"key":"2022051215233670500_B8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.exphem.2021.02.011","article-title":"Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations","volume":"97","author":"Tan","year":"2021","journal-title":"Exp Hematol."},{"key":"2022051215233670500_B9","article-title":"Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells [published online ahead of print 10 January 2022]","author":"Ge","journal-title":"Blood Adv."},{"issue":"3","key":"2022051215233670500_B10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0609.2000.90052.x","article-title":"Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia","volume":"64","author":"Andr\u00e9asson","year":"2000","journal-title":"Eur J Haematol."},{"issue":"1","key":"2022051215233670500_B11","first-page":"17","article-title":"From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol."},{"issue":"7","key":"2022051215233670500_B12","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood."},{"issue":"29","key":"2022051215233670500_B13","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022051215233670500_B14","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022051215233670500_B15","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia."},{"issue":"22","key":"2022051215233670500_B16","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood."},{"issue":"16","key":"2022051215233670500_B17","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2020005563","article-title":"JAK2-V617F and interferon-\u03b1 induce megakaryocyte-biased stem cells characterized by decreased long-term functionality","volume":"137","author":"Rao","year":"2021","journal-title":"Blood."},{"issue":"18","key":"2022051215233670500_B18","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood."},{"issue":"8","key":"2022051215233670500_B19","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood."},{"issue":"8","key":"2022051215233670500_B20","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood."},{"issue":"32","key":"2022051215233670500_B21","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022051215233670500_B22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood."},{"issue":"9","key":"2022051215233670500_B23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leuk Res."},{"issue":"10","key":"2022051215233670500_B24","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon \u03b1-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica."},{"issue":"18","key":"2022051215233670500_B25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood."},{"issue":"23","key":"2022051215233670500_B26","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2022051215233670500_B27","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"2022051215233670500_B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136973","article-title":"Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension","volume":"136","author":"Gisslinger","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2022051215233670500_B29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1358\/dot.2020.56.3.3107706","article-title":"Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera","volume":"56","author":"Wagner","year":"2020","journal-title":"Drugs Today (Barc)."},{"issue":"3","key":"2022051215233670500_B30","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022051215233670500_B31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med."},{"issue":"2","key":"2022051215233670500_B32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med."},{"issue":"5","key":"2022051215233670500_B33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.23970","article-title":"Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis","volume":"90","author":"Barbui","year":"2015","journal-title":"Am J Hematol."},{"issue":"19","key":"2022051215233670500_B34","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","article-title":"n-3 fatty acids in patients with multiple cardiovascular risk factors","volume":"368","author":"Roncaglioni","year":"2013","journal-title":"N Engl J Med."},{"issue":"9678","key":"2022051215233670500_B35","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet."},{"issue":"11","key":"2022051215233670500_B36","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv."},{"issue":"4","key":"2022051215233670500_B37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood."},{"issue":"19","key":"2022051215233670500_B38","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood."},{"issue":"6","key":"2022051215233670500_B39","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/10428194.2016.1246733","article-title":"The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts","volume":"58","author":"Scherber","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"9","key":"2022051215233670500_B40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med."},{"issue":"9","key":"2022051215233670500_B41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med."},{"issue":"10","key":"2022051215233670500_B42","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022051215233670500_B43","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med."},{"issue":"6","key":"2022051215233670500_B44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol."},{"issue":"6","key":"2022051215233670500_B45","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood."},{"issue":"3","key":"2022051215233670500_B46","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022051215233670500_B47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022051215233670500_B48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"176","author":"Mesa","year":"2017","journal-title":"Br J Haematol."},{"issue":"1","key":"2022051215233670500_B49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/hematology.2019001318","article-title":"From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms","volume":"2019","author":"Stein","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"1","key":"2022051215233670500_B50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer."},{"issue":"5","key":"2022051215233670500_B51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med."},{"issue":"6","key":"2022051215233670500_B52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11739-011-0634-3","article-title":"Polycythemia vera: gender-related phenotypic differences","volume":"7","author":"Landolfi","year":"2012","journal-title":"Intern Emerg Med."},{"issue":"9","key":"2022051215233670500_B53","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia."},{"key":"2022051215233670500_B54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2021-147869","article-title":"A JAK2V617F variant allele frequency greater than 50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"138","author":"Losococco","year":"2021","journal-title":"Blood."},{"issue":"1","key":"2022051215233670500_B55","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","article-title":"The effect of arterial hypertension on thrombosis in low-risk polycythemia vera","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol."},{"issue":"26","key":"2022051215233670500_B56","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood."},{"issue":"7","key":"2022051215233670500_B57","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood."},{"issue":"6","key":"2022051215233670500_B58","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood."},{"issue":"17","key":"2022051215233670500_B59","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med."},{"issue":"1","key":"2022051215233670500_B60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2022051215233670500_B61","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood."},{"issue":"34","key":"2022051215233670500_B62","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022051215233670500_B63","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol."},{"issue":"11","key":"2022051215233670500_B64","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol."},{"key":"2022051215233670500_B65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2021-148020","article-title":"European LeukemiaNet (ELN) response predicts disease progression but not thrombosis or death in polycythemia vera (PV): an analysis of a multicenter database","volume":"138","author":"Tremblay","year":"2021","journal-title":"Blood."},{"key":"2022051215233670500_B66","doi-asserted-by":"crossref","first-page":"106629","DOI":"10.1016\/j.leukres.2021.106629","article-title":"Ruxolitinib discontinuation in polycythemia vera: patient characteristics, outcomes, and salvage strategies from a large multi-institutional database","volume":"109","author":"Tremblay","year":"2021","journal-title":"Leuk Res."},{"key":"2022051215233670500_B67","article-title":"Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study","author":"Zwicker","journal-title":"Haematologica."},{"key":"2022051215233670500_B68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2021-148509","article-title":"A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera (analysis of data from the REVEAL study)","volume":"138","author":"Gerds","year":"2021","journal-title":"Blood."},{"key":"2022051215233670500_B69","article-title":"Television interview between anchor Linsey Davis and journalist Carl Bernstein about his new book Chasing History: A Kid in the Newsroom","author":"ABC News LivePrime","year":"2022"},{"key":"2022051215233670500_B70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-141796","article-title":"Interferon in polycythemia vera (PV) yields improved myelofibrosis-free and overall survival","volume":"136","author":"Abu-Zeinah","year":"2020","journal-title":"Blood."},{"key":"2022051215233670500_B71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2021-147061","article-title":"Normal life expectancy for polycythemia vera patients is possible","volume":"138","author":"Abu-Zeinah","year":"2021","journal-title":"Blood."},{"issue":"2","key":"2022051215233670500_B72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood."},{"issue":"33","key":"2022051215233670500_B73","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol."},{"issue":"24","key":"2022051215233670500_B74","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood."},{"issue":"2","key":"2022051215233670500_B75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022051215233670500_B76","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1002\/cam4.3380","article-title":"Depressive symptoms and myeloproliferative neoplasms: understanding the confounding factor in a complex condition","volume":"9","author":"Padrnos","year":"2020","journal-title":"Cancer Med."},{"issue":"12","key":"2022051215233670500_B77","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.30013","article-title":"The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: an analysis by the MPN QOL International Study Group","volume":"122","author":"Geyer","year":"2016","journal-title":"Cancer."},{"issue":"10","key":"2022051215233670500_B78","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol."},{"issue":"3","key":"2022051215233670500_B79","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer."},{"issue":"6","key":"2022051215233670500_B80","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood."},{"key":"2022051215233670500_B81","article-title":"MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study [published online ahead of print 21 December 2021]","author":"Mascarenhas","journal-title":"Blood Adv."},{"key":"2022051215233670500_B82","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2019-123546","article-title":"A randomized, open-label, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of KRT-232 compared with ruxolitinib in patients with phlebotomy-dependent polycythemia vera [abstract]","volume":"134","author":"Gotlib","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2022051215233670500_B83","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"HemaSphere."},{"issue":"3","key":"2022051215233670500_B84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-021-00445-z","article-title":"Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1\/2 studies and a compassionate use program","volume":"11","author":"Rambaldi","year":"2021","journal-title":"Blood Cancer J."},{"issue":"10","key":"2022051215233670500_B85","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia."},{"issue":"2","key":"2022051215233670500_B86","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3324\/haematol.2019.232124","article-title":"Iron metabolism and iron disorders revisited in the hepcidin era","volume":"105","author":"Camaschella","year":"2020","journal-title":"Haematologica."},{"issue":"12","key":"2022051215233670500_B87","doi-asserted-by":"crossref","first-page":"e0251995","DOI":"10.1371\/journal.pone.0251995","article-title":"Tmprss6-ASO as a tool for the treatment of polycythemia vera mice","volume":"16","author":"Casu","year":"2021","journal-title":"PLoS One."},{"key":"2022051215233670500_B88","first-page":"388","article-title":"Rusfertide (PTG-300) controls hematocrit levels and essentially eliminates phlebotomy requirement in polycythemia vera patients","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood."},{"key":"2022051215233670500_B89","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2021-149219","article-title":"A phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera","volume":"138","author":"Verstovsek","year":"2021","journal-title":"Blood."},{"issue":"3","key":"2022051215233670500_B90","doi-asserted-by":"crossref","first-page":"e0247858","DOI":"10.1371\/journal.pone.0247858","article-title":"Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms","volume":"16","author":"Baik","year":"2021","journal-title":"PLoS One."},{"issue":"5","key":"2022051215233670500_B91","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11899-021-00647-z","article-title":"Philadelphia-negative myeloproliferative neoplasms around the COVID-19 pandemic","volume":"16","author":"Barbui","year":"2021","journal-title":"Curr Hematol Malig Rep."},{"key":"2022051215233670500_B92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2021-146029","article-title":"Excess mortality in young patients with myeloproliferative neoplasms","volume":"138","author":"Abu-Zeinah","year":"2021","journal-title":"Blood."},{"key":"2022051215233670500_B93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-141223","article-title":"Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission","volume":"136","author":"De Oliviera","year":"2021","journal-title":"Blood."},{"issue":"3","key":"2022051215233670500_B94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French STOP Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022051215233670500_B95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"issue":"10","key":"2022051215233670500_B96","doi-asserted-by":"crossref","first-page":"100425","DOI":"10.1016\/j.xcrm.2021.100425","article-title":"Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms","volume":"2","author":"Shen","year":"2021","journal-title":"Cell Rep Med."},{"issue":"1","key":"2022051215233670500_B97","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(21)00343-4","article-title":"Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials","volume":"9","author":"Mazza","year":"2022","journal-title":"Lancet Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/19\/2871\/1896531\/bloodbld2022015680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/19\/2871\/1896531\/bloodbld2022015680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T20:14:52Z","timestamp":1674936892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/19\/2871\/484365\/Treatment-and-clinical-endpoints-in-polycythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":97,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015680","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}